Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent

(MedPage Today) -- Patients with previously treated dermatomyositis had significant improvement in skin-related symptoms and quality of life when treated with the selective TYK2/JAK1 inhibitor brepocitinib (Lisraya), data from a randomized trial...

Read it at MedPage Today ↗

Join the argument

House rules →

Comments load as you scroll.

← Front page

Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent — SignalPop